AgMedica Bioscience Inc. (“AGMEDICA” or the “Company”), a licensed producer of medicinal cannabis, is pleased to announce that the Company has closed the acquisition of two indoor processing facilities, designed to bolster the Company’s future production and cultivation capabilities and supplement its existing infrastructure.

The first facility is located in London, Ontario and features 100,000 square feet (“sq. ft”) for fully automated processing, packaging and bottling.   With this additional capacity, AGMEDICA is positioned to further expand its oil extraction capabilities and leverage the recently announced strategic investment in, and licencing agreement with, Herbolea S.r.l.


The second facility is located in Chatham, Ontario and provides 300,000 sq. ft that is ideally suited for future cannabis-plant cultivation.

In addition to these new facilities, AGMEDICA continues to enhance its existing properties.  The Company’s Phase I Riverview cultivation site is 200,000 sq. ft and has indoor capacity of 6,000 kg of cannabis annually.  The Phase II expansion of the Riverview facility is underway which will bring total capacity to 26,500 kg annually, with completion of the expansion anticipated in Q1 2019.  The Company’s existing Richmond cultivation facility features 130,000 sq. ft of cultivation, while a second Richmond site provides nearly 40,000 sq. ft established strictly for tissue cultures.  This state-of-the-art facility has capacity to produce for both AGMEDICA and other third-party licensed producers (“LPs”).

Including the two recent acquisitions, the Company now has five facilities, providing a combined total of over 760,000 sq. ft of cultivation and pharma-grade, multi-tier production capacity for AGMEDICA.  With this footprint, the Company can cost-effectively increase output per sq. ft of floor space with leading energy efficiencies and boasts one of the largest initial capacities of any first-time cannabis producer in Canada.

The addition of these important facilities meaningfully enhances the Company’s production and sales capabilities and is perfectly aligned with AGMEDICA’s growth strategy to be a leader in the research, manufacture and commercialization of innovative cannabis-derived products that support the health and wellness journey of its human and veterinary clients.

About AgMedica Bioscience Inc.

As a licensed producer of medicinal cannabis, AGMEDICA is dedicated to becoming a global leader in the development and commercialization of cannabis and cannabis-derived products to support the health and wellness of our clients.  We aspire to drive the evolution of the cannabis industry by focussing investment on the development and commercialization of differentiated products in the medicinal, health & wellness and pharmaceutical sectors.  The Company’s established Riverview Cultivation Facility is located in Chatham, Ontario, and Phase I of our first innovative multi-tier cultivation facility is currently in production with a total annual capacity of 6,000 kg of medical-grade cannabis.  Construction on Phase II of the Riverview Cultivation Facility is well under way, with completion and start-up expected in Q1 2019 which will bring total annual capacity up to 26,500 kg. www.agmedica.ca.

For further information: Sengkee Ahn, MBA, FEA, Vice President, Investor Relations and International Business Development, sengkeea@agmedica.ca, Mobile: 1-647-868-6928, www.agmedica.ca

Source: www.newswire.ca

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less

A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.

Meanwhile, a cannabis retail operator elected to celebrate 420 by auctioning a cannabis-themed digital art piece using blockchain technology.

Keep reading... Show less

Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.

Keep reading... Show less

Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola

The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).

Keep reading... Show less